Literature DB >> 1387434

Urinary C3dg and C5b-9 indicate active immune disease in human membranous nephropathy.

P E Brenchley1, B Coupes, C D Short, D J O'Donoghue, F W Ballardie, N P Mallick.   

Abstract

We have measured complement activation markers, C3dg and C5b-9 in plasma and urine from patients with idiopathic membranous nephropathy and IgA nephropathy. There was no significant difference in levels of plasma C5b-9 between the patient groups. However, high plasma concentrations of C3dg were associated significantly with IgA nephropathy with 45% of patients having levels over 25 U/ml (P less than 0.001). High concentrations of urinary C3dg and C5b-9 were associated significantly with membranous nephropathy (43% and 43% of the patient group, respectively) compared to patients with IgA nephropathy (10% and 0%, respectively, P less than 0.001). In a retrospective analysis of 31 patients with membranous nephropathy, 66% of patients with high initial urinary C5b-9 showed an unstable clinical course compared to 18% of patients with initially absent or low C5b-9 (P less than 0.001). We suggest that high urinary C5b-9 identifies those patients with a membranous lesion which retains an active immunological component contributing to the pathology of progressive glomerular damage.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1387434     DOI: 10.1038/ki.1992.143

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  16 in total

Review 1.  Complement activation in progressive renal disease.

Authors:  Amy Fearn; Neil Stephen Sheerin
Journal:  World J Nephrol       Date:  2015-02-06

2.  Experimental Models of Membranous Nephropathy.

Authors:  J Ashley Jefferson; Jeffrey W Pippin; Stuart J Shankland
Journal:  Drug Discov Today Dis Models       Date:  2010

3.  Mouse models of membranous nephropathy: the road less travelled by.

Authors:  Dorin-Bogdan Borza; Jun-Jun Zhang; Laurence H Beck; Catherine Meyer-Schwesinger; Wentian Luo
Journal:  Am J Clin Exp Immunol       Date:  2013-06-15

Review 4.  Unmet challenges in membranous nephropathy.

Authors:  David J Salant
Journal:  Curr Opin Nephrol Hypertens       Date:  2019-01       Impact factor: 2.894

Review 5.  All Things Complement.

Authors:  Joshua M Thurman; Carla M Nester
Journal:  Clin J Am Soc Nephrol       Date:  2016-06-23       Impact factor: 8.237

Review 6.  The role of the alternative pathway of complement activation in glomerular diseases.

Authors:  Emilia Łukawska; Magdalena Polcyn-Adamczak; Zofia I Niemir
Journal:  Clin Exp Med       Date:  2018-02-15       Impact factor: 3.984

7.  Glomerular C3c localization indicates ongoing immune deposit formation and complement activation in experimental glomerulonephritis.

Authors:  M Schulze; C J Pruchno; M Burns; P J Baker; R J Johnson; W G Couser
Journal:  Am J Pathol       Date:  1993-01       Impact factor: 4.307

Review 8.  Therapeutic regulation of complement in patients with renal disease - where is the promise?

Authors:  Johua M Thurman
Journal:  Clin Nephrol       Date:  2012-05       Impact factor: 0.975

9.  Identification of membrane-bound CR1 (CD35) in human urine: evidence for its release by glomerular podocytes.

Authors:  M Pascual; G Steiger; S Sadallah; J P Paccaud; J L Carpentier; R James; J A Schifferli
Journal:  J Exp Med       Date:  1994-03-01       Impact factor: 14.307

Review 10.  Alternative Pathway Dysregulation and the Conundrum of Complement Activation by IgG4 Immune Complexes in Membranous Nephropathy.

Authors:  Dorin-Bogdan Borza
Journal:  Front Immunol       Date:  2016-04-25       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.